| Year |
Citation |
Score |
| 2019 |
Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, et al. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). The Oncologist. PMID 31852811 DOI: 10.1634/Theoncologist.2019-0437 |
0.305 |
|
| 2019 |
Etienne-Grimaldi M, Cozic N, Boyer J, Boige V, Diasio R, Taieb J, Meulendijks D, Palles C, Zanger U, Deenen M, Largiader C, Boisdron-Celle M, Marinaki A, Jennings B, Gross E, et al. FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity Annals of Oncology. 30: v214. DOI: 10.1093/Annonc/Mdz246.046 |
0.328 |
|
| 2018 |
Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Won Kim T, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy. Clinical Pharmacology and Therapeutics. PMID 29923599 DOI: 10.1002/Cpt.1124 |
0.311 |
|
| 2018 |
Siddiqui NS, Purvey S, Hamal R, Zhang L, Diasio RB, Saif WM. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades. Journal of Clinical Oncology. 36: 2576-2576. DOI: 10.1200/Jco.2018.36.15_Suppl.2576 |
0.333 |
|
| 2018 |
Wu R, Nie Q, Kubica PA, Wang Z, Shrestha S, Trogstad-Isaacson CS, Jerde CR, Tapper EE, Bouchonville KJ, Offer SM, Diasio RB. Abstract 911: Targeting the mutant KRAS/BRAF-induced enhancer as an approach to overcome resistance to 5-fluorouracil-based chemotherapy in colorectal cancer Cancer Research. 78: 911-911. DOI: 10.1158/1538-7445.Am2018-911 |
0.364 |
|
| 2018 |
Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Offer SM, Diasio RB. Abstract 3893: Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity Cancer Research. 78: 3893-3893. DOI: 10.1158/1538-7445.Am2018-3893 |
0.367 |
|
| 2017 |
Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, ... ... Diasio RB, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet. Oncology. 18: e653-e706. PMID 29208398 DOI: 10.1016/S1470-2045(17)30698-8 |
0.307 |
|
| 2017 |
Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB. Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clinical Pharmacology and Therapeutics. PMID 28295243 DOI: 10.1002/Cpt.685 |
0.316 |
|
| 2017 |
Flores JP, Diasio RB, Saif MW. Drug metabolism and pancreatic cancer. Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology. 30: 54-61. PMID 28042238 DOI: 10.20524/Aog.2016.0074 |
0.345 |
|
| 2016 |
Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, Sarangi V, Roberts LR, Offer SM, Diasio RB. Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clinical Pharmacology and Therapeutics. PMID 27727460 DOI: 10.1002/Cpt.531 |
0.351 |
|
| 2016 |
Saif MW, Smith MH, Maloney A, Diasio RB. Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology. 29: 551-556. PMID 27708529 DOI: 10.20524/Aog.2016.0053 |
0.365 |
|
| 2016 |
Wu R, Nie Q, Tapper EE, Jerde CR, Dunlap GS, Shrestha S, Elraiyah TA, Offer SM, Diasio RB. Histone H3K27 trimethylation modulates 5-fluorouracil resistance by inhibiting PU.1 binding to the DPYD promoter. Cancer Research. PMID 27578004 DOI: 10.1158/0008-5472.Can-16-1306 |
0.343 |
|
| 2016 |
Saif MW, Diasio RB. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. Cancer Chemotherapy and Pharmacology. PMID 27278667 DOI: 10.1007/S00280-016-3063-1 |
0.367 |
|
| 2016 |
Saif MW, Wasif K, Butler-Bowen H, Miller K, Diasio RB. Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient. Therapeutic Advances in Gastroenterology. 9: 121-7. PMID 26770273 DOI: 10.1177/1756283X15604115 |
0.326 |
|
| 2016 |
Offer SM, Diasio RB. Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 205-7. PMID 26644533 DOI: 10.1200/Jco.2015.64.2546 |
0.339 |
|
| 2016 |
Wu R, Offer S, Jerde C, Dunlap G, Diasio R. Abstract B49: Histone H3K27 tri-methylation regulates DPYD expression and cellular sensitivity of 5-fluorouracil Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B49 |
0.323 |
|
| 2016 |
Shrestha S, Offer SM, Diasio RB. Abstract LB-195: The intronic DPYD variant rs75017182 correlates with a modest reduction in DPD enzyme activity Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-195 |
0.369 |
|
| 2015 |
Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenetics and Genomics. PMID 26658227 DOI: 10.1097/Fpc.0000000000000197 |
0.362 |
|
| 2015 |
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzi?ski M, et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications. 6: 7539. PMID 26198393 DOI: 10.1038/Ncomms8539 |
0.329 |
|
| 2015 |
Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) to predict toxicity in stage III colon cancer (CC) patients (pts) (NCCTG Alliance N0147). Journal of Clinical Oncology. 33: 508-508. DOI: 10.1200/Jco.2015.33.3_Suppl.508 |
0.318 |
|
| 2015 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Wiktor AE, Diasio RB, Wu T, Jenkins RB, Sinicrope FA. Comparison of HER2 gene amplification (AMP) in primary esophageal and gastroesophageal junction adenocarcinomas (EAC) and their metastatic regional lymph nodes (MLNs). Journal of Clinical Oncology. 33: 4059-4059. DOI: 10.1200/Jco.2015.33.15_Suppl.4059 |
0.311 |
|
| 2014 |
Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3319-27. PMID 24727325 DOI: 10.1158/1078-0432.Ccr-14-0069 |
0.327 |
|
| 2014 |
Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Research. 74: 2545-54. PMID 24648345 DOI: 10.1158/0008-5472.Can-13-2482 |
0.404 |
|
| 2014 |
Lee AM, Diasio RB. Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 989-90. PMID 24590640 DOI: 10.1200/Jco.2013.53.4479 |
0.402 |
|
| 2014 |
Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clinic Proceedings. 89: 131-6. PMID 24388031 DOI: 10.1016/j.mayocp.2013.09.008 |
0.33 |
|
| 2014 |
Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 120: 415-24. PMID 24151090 DOI: 10.1002/Cncr.28435 |
0.306 |
|
| 2014 |
Offer SM, Diasio RB. Response to "a case of 5-FU-Related severe toxicity associated with the P.Y186C DPYD Variant" Clinical Pharmacology and Therapeutics. 95: 137. PMID 24107927 DOI: 10.1038/Clpt.2013.207 |
0.324 |
|
| 2013 |
Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clinical Pharmacology and Therapeutics. 94: 640-5. PMID 23988873 DOI: 10.1038/Clpt.2013.172 |
0.381 |
|
| 2013 |
Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clinical Pharmacology and Therapeutics. 94: 158-66. PMID 23588312 DOI: 10.1038/Clpt.2013.69 |
0.758 |
|
| 2013 |
Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Research. 73: 1958-68. PMID 23328581 DOI: 10.1158/0008-5472.Can-12-3858 |
0.404 |
|
| 2013 |
Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 79: 27-32. PMID 23079156 DOI: 10.1016/J.Lungcan.2012.09.013 |
0.315 |
|
| 2013 |
Lee A, Shi Q, Pavey ES, Sargent DJ, Alberts SR, Sinicrope FA, Berenberg J, Goldberg RM, Diasio RB. Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. Journal of Clinical Oncology. 31: 3510-3510. DOI: 10.1200/Jco.2013.31.15_Suppl.3510 |
0.36 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3932-8. PMID 22987085 DOI: 10.1200/Jco.2012.43.1890 |
0.331 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 546-54. PMID 22252257 DOI: 10.1158/1078-0432.Ccr-11-2272 |
0.304 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Wiktor AE, Wu T, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology. 30: 4009-4009. DOI: 10.1200/Jco.2012.30.15_Suppl.4009 |
0.342 |
|
| 2012 |
Sloan JA, Shi Q, Lee A, Diasio RB, Pavey ES, Sargent DJ, Goldberg RM, Sinicrope FA, Mahoney MR, Alberts SR. Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). Journal of Clinical Oncology. 30: 3617-3617. DOI: 10.1200/Jco.2012.30.15_Suppl.3617 |
0.33 |
|
| 2012 |
Sha D, Lee A, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 microRNA-binding site polymorphism in 3'-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147. Journal of Clinical Oncology. 30: 3564-3564. DOI: 10.1200/Jco.2012.30.15_Suppl.3564 |
0.37 |
|
| 2012 |
Gupta M, Hu G, Offer S, Maurer MJ, Wellik L, Han JJ, Dogan A, Diasio RB, Witzig TE. Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes. Blood. 120: 2655-2655. DOI: 10.1182/Blood.V120.21.2655.2655 |
0.308 |
|
| 2011 |
Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu T, Diasio RB, Jenkins RB, Sinicrope F. HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4012. PMID 28020553 DOI: 10.1200/Jco.2011.29.15_Suppl.4012 |
0.328 |
|
| 2011 |
Lee AM, Moertel J, Wang K, Diasio RB. Abstract 5451: High-throughput detection of dihydropyrimidine dehydrogenase gene (DPYD) variants using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) Cancer Research. 71: 5451-5451. DOI: 10.1158/1538-7445.Am2011-5451 |
0.411 |
|
| 2011 |
Offer SM, Wegner NJ, Diasio RB. Abstract 4404: Post-transcriptional regulation of dihydropyrimidine dehydrogenase (DPD) by the microRNAs mir27a and mir27b Cancer Research. 71: 4404-4404. DOI: 10.1158/1538-7445.Am2011-4404 |
0.365 |
|
| 2010 |
Saif MW, Sellers S, Diasio RB, Douillard JY. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anti-Cancer Drugs. 21: 716-23. PMID 20581657 DOI: 10.1097/Cad.0B013E32833Cb658 |
0.33 |
|
| 2010 |
Lee AM, Diasio RB. ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3319-21. PMID 20570925 DOI: 10.1158/1078-0432.Ccr-10-1059 |
0.324 |
|
| 2009 |
Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R. A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4083. PMID 27961640 DOI: 10.1200/Jco.2009.27.15_Suppl.4083 |
0.309 |
|
| 2009 |
Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB. (13)C-5-FU breath test current status and future directions: a comprehensive review. Journal of Breath Research. 3: 047002. PMID 21386199 DOI: 10.1088/1752-7155/3/4/047002 |
0.764 |
|
| 2009 |
Saif MW, Hashmi S, Bell D, Diasio RB. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Expert Opinion On Drug Safety. 8: 507-14. PMID 19663627 DOI: 10.1517/14740330903173217 |
0.341 |
|
| 2008 |
Saif MW, Seller S, Diasio RB. Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor? Jop : Journal of the Pancreas. 9: 226-9. PMID 18326935 |
0.303 |
|
| 2008 |
Ezzeldin HH, Diasio RB. Predicting fluorouracil toxicity: can we finally do it? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2080-2. PMID 18299611 DOI: 10.1200/Jco.2007.15.5481 |
0.461 |
|
| 2008 |
Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, Diasio RB, Iacopetta B. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 915-9. PMID 18245778 DOI: 10.1093/Annonc/Mdm599 |
0.365 |
|
| 2008 |
Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenetics and Genomics. 18: 25-35. PMID 18216719 DOI: 10.1097/Fpc.0B013E3282F2F134 |
0.778 |
|
| 2008 |
Lustberg MB, Bekaii-Saab TS, Diasio R, Ezzeldin H, Starrett SL, Otterson GA, Villalona MA. Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts) Journal of Clinical Oncology. 26: 19090-19090. DOI: 10.1200/Jco.2008.26.15_Suppl.19090 |
0.338 |
|
| 2007 |
Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. Pakistan Journal of Medical Sciences. 23: 832-839. PMID 18846242 DOI: 10.1200/Jco.2006.24.18_Suppl.2056 |
0.784 |
|
| 2007 |
Saif MW, Juneja V, Black G, Thronton J, Johnson MR, Diasio RB. Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Supportive Cancer Therapy. 4: 211-8. PMID 18632519 DOI: 10.3816/Sct.2007.N.017 |
0.334 |
|
| 2007 |
Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenetics and Genomics. 17: 973-87. PMID 18075467 DOI: 10.1097/Fpc.0B013E3282F01788 |
0.777 |
|
| 2007 |
Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer Journal (Sudbury, Mass.). 13: 247-56. PMID 17762760 DOI: 10.1097/Ppo.0B013E31813C12B8 |
0.324 |
|
| 2007 |
Zhang X, Soong R, Wang K, Li L, Davie JR, Guarcello V, Diasio RB. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 85: 337-46. PMID 17612628 DOI: 10.1139/o07-009 |
0.304 |
|
| 2007 |
O'Dwyer PJ, Eckhardt SG, Haller DG, Tepper J, Ahnen D, Hamilton S, Benson AB, Rothenberg M, Petrelli N, Lenz HJ, Diasio R, DuBois R, Sargent D, Sloan J, Johnson CD, et al. Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2313-21. PMID 17538178 DOI: 10.1200/Jco.2006.08.6900 |
0.317 |
|
| 2007 |
Zhang X, Diasio RB. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics. 8: 257-65. PMID 17324113 DOI: 10.2217/14622416.8.3.257 |
0.444 |
|
| 2007 |
Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemotherapy and Pharmacology. 60: 503-7. PMID 17165084 DOI: 10.1007/S00280-006-0392-5 |
0.339 |
|
| 2007 |
Hashmi S, Black G, Bell D, Steg A, Johnson M, Diasio RB, Saif MW. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase (TP) and its correlation with survival Journal of Clinical Oncology. 25: 4606-4606. DOI: 10.1200/Jco.2007.25.18_Suppl.4606 |
0.311 |
|
| 2007 |
Guarcello V, Fourie J, Lawton MJ, Peters WW, Heslin MJ, Diasio RB. Elucidating the mechanisms responsible for the previous failure of phase III clinical trials with eniluracil (EU) and development of a novel scheduling approach to optimize the efficacy of EU/5-fluorouracil (5-FU) combination therapy Journal of Clinical Oncology. 25: 2557-2557. DOI: 10.1200/Jco.2007.25.18_Suppl.2557 |
0.357 |
|
| 2007 |
Fourie J, Mattison LK, Wood TE, Posey JA, Modak A, Diasio RB. The 2-13C-5-fluorouracil breath test (FUBT) as a novel, rapid method for assessment of dihydropyrimidine dehydrogenase (DPD) activity in cancer patients: Initial characterization and comparison to the 2-13C-uracil breath test (UraBT) Journal of Clinical Oncology. 25: 2551-2551. DOI: 10.1200/Jco.2007.25.18_Suppl.2551 |
0.764 |
|
| 2006 |
Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clinical Colorectal Cancer. 6: 219-23. PMID 17026792 DOI: 10.3816/Ccc.2006.N.039 |
0.39 |
|
| 2006 |
Saif MW, Hashmi S, Mattison L, Donovan WB, Diasio RB. Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Anti-Cancer Drugs. 17: 1095-8. PMID 17001184 DOI: 10.1097/01.Cad.0000231479.30524.0E |
0.744 |
|
| 2006 |
Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5491-5. PMID 17000684 DOI: 10.1158/1078-0432.Ccr-06-0747 |
0.773 |
|
| 2006 |
Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB. The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochimica Et Biophysica Acta. 1759: 247-56. PMID 16806531 DOI: 10.1016/J.Bbaexp.2006.05.001 |
0.375 |
|
| 2006 |
Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE, Wang W, Gillespie GY, Johnson MR. Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). Journal of Neuro-Oncology. 80: 261-74. PMID 16773218 DOI: 10.1007/S11060-006-9191-4 |
0.338 |
|
| 2006 |
Saif MW, Black G, Johnson M, Russo S, Diasio R. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemotherapy and Pharmacology. 58: 771-5. PMID 16552574 DOI: 10.1007/S00280-006-0223-8 |
0.313 |
|
| 2006 |
Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clinical Colorectal Cancer. 5: 359-62. PMID 16512996 DOI: 10.3816/Ccc.2006.N.007 |
0.412 |
|
| 2006 |
Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. The Journal of Molecular Diagnostics : Jmd. 8: 76-83. PMID 16436637 DOI: 10.2353/Jmoldx.2006.040402 |
0.726 |
|
| 2006 |
Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 549-55. PMID 16428499 DOI: 10.1158/1078-0432.Ccr-05-2020 |
0.759 |
|
| 2006 |
Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemotherapy and Pharmacology. 58: 396-401. PMID 16421754 DOI: 10.1007/S00280-005-0174-5 |
0.725 |
|
| 2006 |
Juneja V, Black G, Thornton J, Russo S, Johnson M, Diasio R, Saif MW. Hand-foot syndrome (HFS) in patients treated with capecitabine (CAP) and the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) Journal of Clinical Oncology. 24: 8615-8615. DOI: 10.1200/Jco.2006.24.18_Suppl.8615 |
0.311 |
|
| 2006 |
Reed HA, Ezzeldin HH, Mattison LK, Diasio RB. Molecular basis of altered uracil catabolism in individuals with 5-FU toxicity and normal DPD enzyme activity Journal of Clinical Oncology. 24: 3070-3070. DOI: 10.1200/Jco.2006.24.18_Suppl.3070 |
0.787 |
|
| 2006 |
Fourie J, Guarcello V, Diasio RB. Dose dependent inhibition of uridine phosphorylase (UP) by eniluracil (EU): Was the clinical inferiority of the EU/5-fluorouracil (5-FU) phase III trials due to an unrecognized inhibition of 5-FU anabolism? Journal of Clinical Oncology. 24: 2058-2058. DOI: 10.1200/Jco.2006.24.18_Suppl.2058 |
0.345 |
|
| 2006 |
Soong RC, Shah N, Salto-Tellez M, Han HC, Ng SS, Zeps N, Joseph D, Diasio RB, Iacopetta BJ. Prognostic and predictive significance of 5-fluorouracil metabolic enzymes in colorectal cancer Journal of Clinical Oncology. 24: 2021-2021. DOI: 10.1200/Jco.2006.24.18_Suppl.2021 |
0.374 |
|
| 2006 |
Roy S, Russo S, Black G, Eloubeidi MA, Steg A, Zelterman D, Johnson MR, Diasio RB, Saif MW. Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer Journal of Clinical Oncology. 24: 14001-14001. DOI: 10.1200/Jco.2006.24.18_Suppl.14001 |
0.326 |
|
| 2006 |
MATTISON L, ACOSTA E, FOURIE J, DIASIO R. LBOVI-B-2Describing the catabolism of orally administered 2-13C-uracil in normal and dihydropyrimidine dehydrogenase deficient subjects using a parent/metabolite/breath model Clinical Pharmacology & Therapeutics. 79: P83-P83. DOI: 10.1016/J.Clpt.2005.12.298 |
0.748 |
|
| 2005 |
Mattison LK, Fourie J, Carpenter M, Ezzeldin H, Johnson MR, Saif M, Modak A, Diasio RB. Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2004. PMID 27946814 DOI: 10.1200/Jco.2005.23.16_Suppl.2004 |
0.772 |
|
| 2005 |
Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8773-81. PMID 16361565 DOI: 10.1158/1078-0432.Ccr-05-0627 |
0.735 |
|
| 2005 |
Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8699-705. PMID 16361556 DOI: 10.1158/1078-0432.Ccr-05-1520 |
0.776 |
|
| 2005 |
Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8679-87. PMID 16314628 DOI: 10.1200/Jco.2005.02.0628 |
0.739 |
|
| 2005 |
Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics. 6: 835-47. PMID 16296946 DOI: 10.2217/14622416.6.8.835 |
0.341 |
|
| 2005 |
Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M, Kiechle M, Diasio R, Gross E. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of caucasian individuals Clinical Cancer Research. 11: 5886-5892. PMID 16115930 DOI: 10.1158/1078-0432.Ccr-04-1784 |
0.405 |
|
| 2005 |
Saif MW, Diasio RB. Edotecarin: a novel topoisomerase I inhibitor. Clinical Colorectal Cancer. 5: 27-36. PMID 15929804 DOI: 10.3816/Ccc.2005.N.014 |
0.338 |
|
| 2005 |
Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell T, Nuovo G, Soong R, Diasio R, Villalona-Calero MA. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1870-6. PMID 15756012 DOI: 10.1158/1078-0432.Ccr-04-1727 |
0.304 |
|
| 2004 |
Mattison LK, Johnson MR, Saif W, Modak AS, Hirao Y, Koga T, Shimizu T, Diasio RB. Validation of a novel [2-(13)C]-uracil breath test (UraBT) to detect dihydropyrimidine dehydrogenase (DPD) deficiency by LC-MS-MS analysis of [2-(13)C]-uracil (URA) and [2-(13)C]-dihydrouracil (DHU) plasma levels. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2130. PMID 28016902 DOI: 10.1200/Jco.2004.22.14_Suppl.2130 |
0.761 |
|
| 2004 |
Meropol NJ, Gold PJ, Diasio RB, Chen YM, Godfrey T, Hill T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3520. PMID 28016533 DOI: 10.1200/Jco.2004.22.14_Suppl.3520 |
0.392 |
|
| 2004 |
Newman AJ, Fiveash J, Rosenfeld S, Johnson M, Diasio R, Wang W, Cockrell-Donohue A, Nabors LB. A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1537. PMID 28015410 DOI: 10.1200/Jco.2004.22.14_Suppl.1537 |
0.354 |
|
| 2004 |
Ozer H, Diasio RB. Perspectives in the treatment of colorectal cancer. Seminars in Oncology. 31: 14-8. PMID 15726534 DOI: 10.1053/J.Seminoncol.2004.11.023 |
0.333 |
|
| 2004 |
Saif MW, Wood TE, McGee PJ, Diasio RB. Peripheral neuropathy associated with capecitabine. Anti-Cancer Drugs. 15: 767-71. PMID 15494638 DOI: 10.1097/00001813-200409000-00005 |
0.353 |
|
| 2004 |
Ezzeldin H, Hoffmayer C, Soong R, Johnson MR, Lee A, Heslin M, Diasio R. Simultaneous detection of variable number tandem repeats, single nucleotide polymorphisms, and allelic imbalance in the thymidylate synthase gene enhancer region using denaturing high-performance liquid chromatography. Analytical Biochemistry. 334: 276-83. PMID 15494134 DOI: 10.1016/J.Ab.2004.07.025 |
0.304 |
|
| 2004 |
Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clinical Colorectal Cancer. 4: 181-9. PMID 15377401 DOI: 10.3816/Ccc.2004.N.018 |
0.389 |
|
| 2004 |
Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2652-8. PMID 15102667 DOI: 10.1158/1078-0432.Ccr-03-0374 |
0.777 |
|
| 2003 |
Heslin MJ, Yan J, Weiss H, Shao L, Owens J, Lucas VS, Diasio RB. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 52: 399-404. PMID 12904894 DOI: 10.1007/S00280-003-0681-1 |
0.346 |
|
| 2002 |
Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Molecular Cancer Therapeutics. 1: 1139-45. PMID 12481438 |
0.7 |
|
| 2002 |
Diasio RB. Can eniluracil improve 5-fluorouracil therapy? Clinical Colorectal Cancer. 2: 53. PMID 12453337 DOI: 10.1016/S1533-0028(11)70503-5 |
0.343 |
|
| 2002 |
Kempin S, Gutierrez J, Wilson E, Lowery C, Diasio R. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Cancer Investigation. 20: 992-5. PMID 12449732 DOI: 10.1081/Cnv-120005915 |
0.377 |
|
| 2002 |
Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 3: 485-92. PMID 12164772 DOI: 10.1517/14622416.3.4.485 |
0.788 |
|
| 2002 |
Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Analytical Biochemistry. 306: 63-73. PMID 12069415 DOI: 10.1006/Abio.2002.5666 |
0.351 |
|
| 2002 |
Blanquicett C, Johnson MR, Heslin M, Diasio RB. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Analytical Biochemistry. 303: 209-14. PMID 11950223 DOI: 10.1006/Abio.2001.5570 |
0.719 |
|
| 2002 |
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1683-91. PMID 11896120 DOI: 10.1200/Jco.20.6.1683 |
0.337 |
|
| 2002 |
Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics. 12: 133-44. PMID 11875367 DOI: 10.1097/00008571-200203000-00007 |
0.755 |
|
| 2001 |
Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Advances in Enzyme Regulation. 41: 151-7. PMID 11384742 DOI: 10.1016/S0065-2571(00)00011-X |
0.354 |
|
| 2000 |
Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology. 61: 199-203. PMID 10971206 DOI: 10.1159/000028401 |
0.381 |
|
| 2000 |
Diasio RB. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs. 119-26. PMID 10711850 DOI: 10.2165/00003495-199958003-00016 |
0.316 |
|
| 1997 |
Johnson MR, Yan J, Shao L, Albin N, Diasio RB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. Journal of Chromatography. B, Biomedical Sciences and Applications. 696: 183-91. PMID 9323539 DOI: 10.1016/S0378-4347(97)00253-3 |
0.423 |
|
| 1995 |
Zhang R, Lu Z, Zhang X, Zhao H, Diasio RB, Liu T, Jiang Z, Agrawal S. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clinical Chemistry. 41: 836-43. PMID 7768001 DOI: 10.1093/Clinchem/41.6.836 |
0.375 |
|
| 1995 |
Diasio RB, Van Kuilenburg AB, Lu Z, Zhang R, Van Lenthe H, Bakker HD, Van Gennip AH. Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD. Advances in Experimental Medicine and Biology. 370: 7-10. PMID 7661001 DOI: 10.1007/978-1-4615-2584-4_2 |
0.301 |
|
| 1995 |
Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Van J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Zhang R. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration Biochemical Pharmacology. 50: 571-576. PMID 7646565 DOI: 10.1016/0006-2952(95)00160-2 |
0.378 |
|
| 1995 |
Zhang R, LU Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Agrawal S. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats Biochemical Pharmacology. 50: 545-556. PMID 7646561 DOI: 10.1016/0006-2952(95)00159-W |
0.4 |
|
| 1995 |
Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clinical Pharmacology and Therapeutics. 58: 512-22. PMID 7586945 DOI: 10.1016/0009-9236(95)90171-X |
0.374 |
|
| 1993 |
Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Investigation. 11: 239-40. PMID 8462026 DOI: 10.3109/07357909309024846 |
0.364 |
|
| 1992 |
Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi JP. Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. Clinical Pharmacology and Therapeutics. 51: 668-76. PMID 1611806 DOI: 10.1038/Clpt.1992.79 |
0.306 |
|
| 1991 |
Coustère C, Mentré F, Sommadossi JP, Diasio RB, Steimer JL. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemotherapy and Pharmacology. 28: 123-9. PMID 2060083 DOI: 10.1007/Bf00689701 |
0.332 |
|
| 1991 |
Zhang RW, Barnes S, Diasio RB. Disposition and metabolism of 2-fluoro-beta-alanine conjugates of bile acids following secretion into bile. Biochimica Et Biophysica Acta. 1096: 179-86. PMID 1902118 DOI: 10.1016/0925-4439(91)90003-R |
0.316 |
|
| 1991 |
Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer. 68: 499-501. PMID 1648430 DOI: 10.1002/1097-0142(19910801)68:3<499::Aid-Cncr2820680309>3.0.Co;2-F |
0.416 |
|
| 1989 |
Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clinical Pharmacokinetics. 16: 215-37. PMID 2656050 DOI: 10.2165/00003088-198916040-00002 |
0.331 |
|
| 1988 |
Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. The Journal of Clinical Investigation. 81: 47-51. PMID 3335642 DOI: 10.1172/Jci113308 |
0.396 |
|
| 1987 |
Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, Karam GH, Espinel-Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. The American Journal of Medicine. 83: 236-42. PMID 3303926 DOI: 10.1016/0002-9343(87)90691-7 |
0.308 |
|
| Show low-probability matches. |